Logo image of ALGEN.PA

GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ALGEN - FR0004053510 - Common Stock

2.4 EUR
0 (0%)
Last: 1/14/2026, 7:00:00 PM
Fundamental Rating

4

Taking everything into account, ALGEN scores 4 out of 10 in our fundamental rating. ALGEN was compared to 83 industry peers in the Biotechnology industry. ALGEN has an average financial health and profitability rating. While showing a medium growth rate, ALGEN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year ALGEN was profitable.
  • ALGEN had a negative operating cash flow in the past year.
  • In multiple years ALGEN reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: ALGEN reported negative operating cash flow in multiple years.
ALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M

1.2 Ratios

  • ALGEN has a Return On Assets of 3.31%. This is amongst the best in the industry. ALGEN outperforms 80.72% of its industry peers.
  • The Return On Equity of ALGEN (7.00%) is better than 80.72% of its industry peers.
  • With a decent Return On Invested Capital value of 3.17%, ALGEN is doing good in the industry, outperforming 74.70% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for ALGEN is significantly below the industry average of 12.74%.
Industry RankSector Rank
ROA 3.31%
ROE 7%
ROIC 3.17%
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ALGEN.PA Yearly ROA, ROE, ROICALGEN.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • The Profit Margin of ALGEN (6.14%) is better than 80.72% of its industry peers.
  • ALGEN has a Operating Margin of 5.97%. This is in the better half of the industry: ALGEN outperforms 75.90% of its industry peers.
  • ALGEN has a better Gross Margin (94.91%) than 91.57% of its industry peers.
  • In the last couple of years the Gross Margin of ALGEN has remained more or less at the same level.
Industry RankSector Rank
OM 5.97%
PM (TTM) 6.14%
GM 94.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
ALGEN.PA Yearly Profit, Operating, Gross MarginsALGEN.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

4

2. Health

2.1 Basic Checks

  • ALGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for ALGEN has been reduced compared to 1 year ago.
  • Compared to 5 years ago, ALGEN has more shares outstanding
  • The debt/assets ratio for ALGEN has been reduced compared to a year ago.
ALGEN.PA Yearly Shares OutstandingALGEN.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALGEN.PA Yearly Total Debt VS Total AssetsALGEN.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of 1.73, we must say that ALGEN is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.73, ALGEN is in the better half of the industry, outperforming 67.47% of the companies in the same industry.
  • A Debt/Equity ratio of 0.71 indicates that ALGEN is somewhat dependend on debt financing.
  • ALGEN has a Debt to Equity ratio (0.71) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Altman-Z 1.73
ROIC/WACC0.44
WACC7.19%
ALGEN.PA Yearly LT Debt VS Equity VS FCFALGEN.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M

2.3 Liquidity

  • ALGEN has a Current Ratio of 2.41. This indicates that ALGEN is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.41, ALGEN is in line with its industry, outperforming 51.81% of the companies in the same industry.
  • ALGEN has a Quick Ratio of 2.21. This indicates that ALGEN is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.21, ALGEN is in line with its industry, outperforming 51.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 2.21
ALGEN.PA Yearly Current Assets VS Current LiabilitesALGEN.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

4

3. Growth

3.1 Past

  • ALGEN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.46%.
  • ALGEN shows a decrease in Revenue. In the last year, the revenue decreased by -2.21%.
  • The Revenue has been growing by 18.46% on average over the past years. This is quite good.
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%

3.2 Future

  • ALGEN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by 0.00% yearly.
  • The Revenue is expected to grow by 10.37% on average over the next years. This is quite good.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALGEN.PA Yearly Revenue VS EstimatesALGEN.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
ALGEN.PA Yearly EPS VS EstimatesALGEN.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2023 2024 2027 0.05 0.1 0.15 0.2

2

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 16.00, the valuation of ALGEN can be described as correct.
  • ALGEN's Price/Earnings ratio is rather cheap when compared to the industry. ALGEN is cheaper than 87.95% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.33, ALGEN is valued a bit cheaper.
Industry RankSector Rank
PE 16
Fwd PE N/A
ALGEN.PA Price Earnings VS Forward Price EarningsALGEN.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ALGEN is valued cheaper than 89.16% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.21
ALGEN.PA Per share dataALGEN.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y0%

0

5. Dividend

5.1 Amount

  • ALGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

GENOWAY SA

EPA:ALGEN (1/14/2026, 7:00:00 PM)

2.4

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners7.91%
Ins Owner ChangeN/A
Market Cap22.75M
Revenue(TTM)20.95M
Net Income(TTM)1.29M
Analysts86.67
Price Target6.02 (150.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 16
Fwd PE N/A
P/S 1.09
P/FCF N/A
P/OCF N/A
P/B 1.24
P/tB 1.84
EV/EBITDA 8.21
EPS(TTM)0.15
EY6.25%
EPS(NY)0
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS2.21
BVpS1.94
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.56
Profitability
Industry RankSector Rank
ROA 3.31%
ROE 7%
ROCE 3.94%
ROIC 3.17%
ROICexc 3.17%
ROICexgc 3.91%
OM 5.97%
PM (TTM) 6.14%
GM 94.91%
FCFM N/A
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score3
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Debt/EBITDA 2.88
Cap/Depr 297.91%
Cap/Sales 46.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 2.21
Altman-Z 1.73
F-Score3
WACC7.19%
ROIC/WACC0.44
Cap/Depr(3y)64.02%
Cap/Depr(5y)125.45%
Cap/Sales(3y)10.32%
Cap/Sales(5y)17.64%
Profit Quality(3y)100.54%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
EBIT growth 1Y-28.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200%
EBIT Next 3Y68.69%
EBIT Next 5YN/A
FCF growth 1Y-380.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.89%
OCF growth 3YN/A
OCF growth 5YN/A

GENOWAY SA / ALGEN.PA FAQ

Can you provide the ChartMill fundamental rating for GENOWAY SA?

ChartMill assigns a fundamental rating of 4 / 10 to ALGEN.PA.


What is the valuation status of GENOWAY SA (ALGEN.PA) stock?

ChartMill assigns a valuation rating of 2 / 10 to GENOWAY SA (ALGEN.PA). This can be considered as Overvalued.


What is the profitability of ALGEN stock?

GENOWAY SA (ALGEN.PA) has a profitability rating of 5 / 10.


Can you provide the PE and PB ratios for ALGEN stock?

The Price/Earnings (PE) ratio for GENOWAY SA (ALGEN.PA) is 16 and the Price/Book (PB) ratio is 1.24.


What is the financial health of GENOWAY SA (ALGEN.PA) stock?

The financial health rating of GENOWAY SA (ALGEN.PA) is 4 / 10.